Michael Schenker

18.4k citations
116 papers · 1.8k · 2 hit papers · h-index 20

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 43
    • Colorectal Cancer Treatments and Studies 13
    • Lung Cancer Research Studies 10
    • Lung Cancer Treatments and Mutations 18
    • Gastric Cancer Management and Outcomes 13

Michael Schenker

109 papers receiving 1.8k citations

Michael Schenker's Hit Papers

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. 2024 · 83 citations
830+2+5Years since publication100200300

Peers

Michael Schenker
Comparison fields: 5 of 90
  • Oncology 956
  • Gastroenterology 127
  • Pulmonary and Respiratory Medicine 529
  • Immunology 220
  • Hepatology 77
Replace Woong Sub Koom with:
Woong Sub Koom South Korea
Aurélie Bertaut France
Toshio Sawada Japan
M. Balducci Italy
Najat Mourra France
Yusuke Onozawa Japan
Joseph L. Leach United States
Marcus Tan United States
Chie‐Schin Shih United States
Albiruni Ryan Abdul Razak Canada
Michael Schenker relative to Woong Sub Koom South Korea Woong Sub Koom's profile →
Citations per field
00.5×4.2×
Woong Sub Koom · 1×
Citations per year

Countries citing papers authored by Michael Schenker

Since Specialization
Citations

This map shows the geographic impact of Michael Schenker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schenker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schenker more than expected).

Fields of papers citing papers by Michael Schenker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schenker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schenker. The network helps show where Michael Schenker may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Schenker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Schenker Line = papers co-authored together Michael Schenker links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Hit paper breakdown →
2018382
2 2020140
3 2020101
4
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Hit paper breakdown →
202483
5 201967
6 201966
7 201953
8 201853
9 201950
10 202046
11 201944
12 202438
13
Vascular endothelial growth factor expression and microvessel density--two useful tools for the assessment of prognosis and survival in gastric cancer patients.
201035
14 202032
15 202130
16
Correlations between colposcopy and histologic results from colposcopically directed biopsy in cervical precancerous lesions.
201227
17 201825
18 202123
19 200620
20 200120

About Michael Schenker

Michael Schenker is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Epidemiology and Molecular Biology, having authored 116 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (43 papers), Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (13 papers), Lung Cancer Research Studies (10 papers), Bladder and Urothelial Cancer Treatments (8 papers), Cancer Genomics and Diagnostics (7 papers) and Melanoma and MAPK Pathways (6 papers). The work is most often cited by research in Oncology (956 citations), Gastroenterology (127 citations), Pulmonary and Respiratory Medicine (529 citations), Immunology (220 citations) and Hepatology (77 citations). Michael Schenker has collaborated with scholars based in Romania, United States and France. Frequent co-authors include Lucjan Wyrwicz, Markus Moehler, Narikazu Boku, Min‐Hee Ryu, Se Hoon Park, Ludovic Evesque, Eric Van Cutsem, Janet Hong, M. Lichinitser and María Alsina. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Journal of Plastic Reconstructive & Aesthetic Surgery and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact